Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Payables (2024 - 2025)

Humacyte has reported Payables over the past 2 years, most recently at $5.4 million for Q4 2025.

  • Quarterly results put Payables at $5.4 million for Q4 2025, up 20.36% from a year ago — trailing twelve months through Dec 2025 was $5.4 million (up 20.36% YoY), and the annual figure for FY2025 was $5.4 million, up 20.36%.
  • Payables for Q4 2025 was $5.4 million at Humacyte, down from $9.6 million in the prior quarter.
  • Over the last five years, Payables for HUMA hit a ceiling of $9.6 million in Q3 2025 and a floor of $3.5 million in Q1 2024.